Welcome to our dedicated page for PERKINELMER news (Ticker: PKI), a resource for investors and traders seeking the latest updates and insights on PERKINELMER stock.
PerkinElmer Inc. (symbol: PKI) is a leading global provider of solutions that enable scientists, researchers, and clinicians to tackle complex challenges in science and healthcare. The company's mission is to innovate for a healthier world through unique solutions that serve the diagnostics, life sciences, food, and applied markets.
PerkinElmer collaborates closely with its customers to deliver earlier and more accurate insights. This is supported by the company's deep market knowledge and technical expertise. With a dedicated workforce of approximately 14,000 employees worldwide, PerkinElmer is committed to improving the quality of life, creating healthier families, and sustaining the wellbeing and longevity of people globally.
In 2020, PerkinElmer reported revenues of approximately $3.8 billion and serves customers in 190 countries. Notably, the company is a component of the S&P 500 index, underscoring its significant market presence and financial stability.
Recent Achievements and Current Projects
- Strategic partnerships with key industry players to enhance diagnostic solutions and life sciences research.
- Continuous investment in innovative technologies and solutions that drive earlier and more accurate healthcare insights.
- Expansion of global reach through new product launches tailored to various market needs.
PerkinElmer's commitment to innovation and collaboration makes it a crucial player in the healthcare and scientific research sectors. By leveraging its extensive expertise and comprehensive solutions, the company strives to address the most pressing challenges faced by its customers.
PerkinElmer (NYSE: PKI) and Honeycomb Biotechnologies have launched the innovative HIVETM scRNAseq Solution, designed for single-cell isolation and analysis. This portable device allows the capture, storage, and RNA sequencing of fragile cell types without the need for specialized equipment, enhancing research opportunities. The HIVE solution maintains sample integrity, improving workflow efficiency for multi-site studies. This technology aims to drive advancements in diagnostics and therapeutic development, particularly for academic collaborations and clinical trials.
PerkinElmer, Inc. (NYSE: PKI) announced it will release its third quarter 2021 financial results on November 2, 2021, after market close. The company will host a conference call at 5:00 p.m. ET to discuss the results, featuring CEO Prahlad Singh and CFO Jamey Mock. Investors can access a live audio webcast via the company’s website. A replay of the call will be available after 7:00 p.m. ET on the same day. PerkinElmer reported approximately $3.8 billion in revenue for 2020 and aims to innovate for a healthier world.
PerkinElmer, NYSE:PKI, has received Emergency Use Authorization (EUA) from the FDA for its PKamp Respiratory SARS-CoV-2 RT-PCR Panel 1. This test allows labs to simultaneously detect and differentiate between SARS-CoV-2, influenza A, influenza B, and RSV from respiratory samples. The test aims to streamline testing during the flu season, helping to alleviate confusion from similar symptoms. PerkinElmer's existing CE marking for this test in over 30 countries is also noted. The company reported revenues of approximately $3.8 billion in 2020.
PerkinElmer has received Emergency Use Authorization (EUA) from the U.S. FDA for its Anti-SARS-CoV-2 S1 Curve ELISA (IgG). This assay enables the qualitative and semi-quantitative detection of IgG antibodies against the SARS-CoV-2 S1 antigen in human serum and plasma. It is designed for use by CLIA-certified laboratories and plays a critical role in vaccine development and research on immunity. The assay can be used manually or on various ELISA platforms, enhancing laboratory capabilities in understanding COVID-19 immunity.
PerkinElmer, Inc. (NYSE: PKI) has successfully completed its acquisition of BioLegend for approximately $5.25 billion. This strategic move represents the largest acquisition in PerkinElmer's history, expanding its life science offerings into high-growth sectors such as cytometry and proteogenomics. BioLegend is projected to enhance PerkinElmer's revenue by $380 million and contribute $0.30 to adjusted earnings per share in fiscal year 2022. The integration aims to bolster innovation in therapeutic discovery and improve the overall reagents portfolio.
PerkinElmer (NYSE: PKI) announced the pricing of a total of
PerkinElmer, Inc. (NYSE: PKI) will present at the Baird Global Healthcare Conference on September 14, 2021, at 10:50 a.m. ET. During the virtual event, Steve Willoughby, Vice President of Investor Relations, will discuss the company's strategic priorities. A live audio webcast can be accessed in the Investors section of the company's website, with a replay available for 90 days post-event. PerkinElmer reported approximately $3.8 billion in revenue in 2020 and has over 14,000 employees worldwide.
PerkinElmer reported robust financial results for Q2 2021, with GAAP EPS of $2.19, up from $1.23 in Q2 2020. Revenue surged to $1.228 billion from $812 million, reflecting a growth rate of 51%. Operating income also rose significantly to $332 million, yielding an operating profit margin of 27.1%. The company announced an acquisition of BioLegend for $5.25 billion and raised its full-year guidance to $4.57 billion in revenue and $9.88 in EPS. The acquisition is expected to enhance its market position.
PerkinElmer (NYSE: PKI) has announced an agreement to acquire BioLegend for approximately $5.25 billion in cash and stock, marking the largest transaction in PerkinElmer’s history. This strategic acquisition aims to enhance PerkinElmer’s life science offerings, particularly in high-growth areas like proteogenomics and cell separation. BioLegend is expected to generate around $380 million in revenue for 2022 and will transition into PerkinElmer’s Center of Excellence for research reagents. The deal anticipates earnings accretion of $0.30 per share in the first year.
PerkinElmer, Inc. (NYSE: PKI) announced a quarterly dividend of $0.07 per share on July 23, 2021. The dividend is scheduled for payment on November 12, 2021, to shareholders of record as of October 22, 2021. PerkinElmer reported a revenue of approximately $3.8 billion in 2020 and employs around 14,000 people across 190 countries. The company is also included in the S&P 500 Index.
FAQ
What is the market cap of PERKINELMER (PKI)?
What does PerkinElmer Inc. do?
What is the mission of PerkinElmer Inc.?
How many employees does PerkinElmer Inc. have?
What was PerkinElmer Inc.'s revenue in 2020?
In how many countries does PerkinElmer Inc. serve customers?
What are some of PerkinElmer Inc.'s recent achievements?
How does PerkinElmer Inc. contribute to healthcare?
Is PerkinElmer Inc. part of any major stock index?
What markets does PerkinElmer Inc. serve?
What is a core focus of PerkinElmer Inc.'s partnerships?
